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Background-—Pharmacists-led medication reviews (MRs) are claimed to be effective for the control of cardiovascular diseases;
however, the evidence in the literature is conflicting. The main objective of this meta-analysis was to analyze the impact of
pharmacist-led MRs on cardiovascular disease risk factors overall and in different ambulatory settings while exploring the effects of
different components of MRs.
Methods and Results-—Searches were conducted in PubMed, Web of Science, Embase, the Cumulative Index to Nursing and Allied
Health Literature, and the Cochrane Library Central Register of Controlled Trials database. Randomized and cluster randomized
controlled trials of pharmacist-led MRs compared with usual care were included. Settings were community pharmacies and
ambulatory clinics. The classification used for MRs was the Pharmaceutical Care Network Europe as basic (type 1), intermediate
(type 2), and advanced (type 3). Meta-analyses in therapeutic goals used odds ratios to standardize the effect of each study, and
for continuous data (eg, systolic blood pressure) raw differences were calculated using baseline and final values, with 95% CIs.
Prediction intervals were calculated to account for heterogeneity. Sensitivity analyses were conducted to test the robustness of
results. Meta-analyses included 69 studies with a total of 11 644 patients. Sample demographic characteristics were similar
between studies. MRs increased control of hypertension (odds ratio, 2.73; 95% prediction interval, 1.05–7.08), type 2 diabetes
mellitus (odds ratio, 3.11; 95% prediction interval, 1.17–5.88), and high cholesterol (odds ratio, 1.91; 95% prediction interval, 1.05–
3.46). In ambulatory clinics, MRs produced significant effects in control of diabetes mellitus and cholesterol. For community
pharmacies, systolic blood pressure and low-density lipoprotein values decreased significantly. Advanced MRs had larger effects
than intermediate MRs in diabetes mellitus and dyslipidemia outcomes. Most intervention components had no significant effect on
clinical outcomes and were often poorly described. CIs were significant in all analyses but prediction intervals were not in
continuous clinical outcomes, with high heterogeneity present.
Conclusions-—Intermediate and advanced MRs provided by pharmacists may improve control of blood pressure, cholesterol, and
type 2 diabetes mellitus, as statistically significant prediction intervals were found. However, most continuous clinical outcomes
failed to achieve statistical significance, with high heterogeneity present, although positive trends and effect sizes were found.
Studies should use a standardized method for MRs to diminish sources of these heterogeneities. ( J Am Heart Assoc. 2019;8:
e013627. DOI: 10.1161/JAHA.119.013627.)
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C ardiovascular diseases (CVDs) are the main cause ofmorbidity and mortality worldwide, with more than 36% of adults in the United States and 40% in Europe at high riskfor developing or with established CVD.1,2 The World Health
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Organization reported 17.9 million of CVD-related deaths in
2016, representing 44% of all deaths from noncommunicable
diseases, with 85% of these deaths caused by strokes and
ischemic heart diseases.3,4 Dyslipidemia, hypertension, and
type 2 diabetes mellitus (T2DM) are the most common risk
factors in adults, with an estimated 39%, 31%, and 8% affected
worldwide, with great impact in mortality, morbidity, and costs
of care. However, common strategies to control these
diseases appear to be relatively ineffective.2–4
Pharmacists are increasingly having direct involvement in
patient care usually by providing services that have the
objective of improving medication management of patients
and other healthcare professionals.5–8 There are various types
of services, including medication reviews (MRs).8,9 MRs vary
from a brief revision of the prescribed medicines to more
complex interventions involving patients and physicians,
which allow the detection of pharmacological interactions
and drug-related problems such as adverse drug reactions,
effectiveness problems, nonadherence, and self-medica-
tion.10,11 Pharmacists-led interventions have reportedly
increased the achievement of therapeutic goals in CVD risk
factors such as hypertension and T2DM, decreasing systolic
blood pressure (BP) between 6 and 10 mm Hg and glycated
hemoglobin (HbA1c) between 0.46% and 1%.
6–10
Some systematic reviews and meta-analyses reveal high
inconsistencies and heterogeneity on the impact of MR.
Possible causes of this problem are the lack of control of
confounding factors such as age and other demographic data,
months of follow-up, control groups without usual care or
dummy interventions, variability, and fidelity of the interven-
tion including different settings.5–10 These specific setting
elements could include access to care teams for proposed
action plans, proximity and relationship with prescribers, the
physical place of the intervention, and other related factors.6–
10 How these differences in ambulatory settings could
influence the clinical impact of the pharmacist’s provision of
MR has not been reported.
The main objective of this meta-analysis was to analyze the
impact of pharmacist-led MRs on CVD risk factors overall and
in different ambulatory settings while exploring the effects of
different components of MRs.
Methods
Data Sources and Searches
A systematic review was performed using the PRISMA state-
ment and Cochrane Collaboration recommendations.12–14 Two
reviewers (F.M.-M., A.A.-C.) performed all of the steps individ-
ually, and any discrepancies were decided by a third author
(V.G.-C.). Searches were conducted in PubMed, Web of
Science, Embase (through Ovid), the Cumulative Index to
Nursing and Allied Health Literature, and the Cochrane Library
Central Register of Controlled Trials database, without any time
limit (up to May 2019). A manual search in the reference lists of
included studies was performed, and grey literature (eg,
Google) was also searched. The complete search strategy for
each database is available in Table S1.
Eligibility Criteria
Table 1 describes inclusion and exclusion criteria. The
Pharmaceutical Care Network Europe (PCNE) categories of
MR conducted by pharmacists were used to classify inter-
ventions as11: type 1: a basic review of medicines and health
problems based on the available medication history in the
pharmacy; type 2: an intermediate review with the available
medication history in the pharmacy and clinical records or
information obtained directly from the patient; and type 3: an
advanced review using medication history, clinical records,
and information obtained directly from the patient.
During the screening phase (title and abstract reading),
articles were excluded if considered irrelevant to the study
goals. The full-text eligibility phase excluded articles that did
not fulfill all of the inclusion criteria.
Data Extraction
Standardized data collection forms were used to extract data on
the studies’ metadata (eg, author names and year), patients’
characteristics (eg, sample size, mean age, sex, and diseases),
type of interventions and its components, setting of intervention,
Clinical Perspective
What Is New?
• Pharmacist-led medication reviews (MRs) seem to improve
the control of hypertension, type 2 diabetes mellitus, and
dyslipidemias in ambulatory settings despite differences in
components implemented and high heterogeneity between
studies.
• MRs in ambulatory clinics could have larger effects in the
achievement of type 2 diabetes mellitus and dyslipidemia
goals and in decreasing systolic blood pressure and low-
density lipoprotein cholesterol in community pharmacies.
• Advanced MRs could have larger effects than intermediate
MRs on diastolic blood pressure, glycated hemoglobin,
fasting glucose, total cholesterol, and low- and high-density
lipoprotein cholesterol, but more studies are needed.
What Are the Clinical Implications?
• Including pharmacists in care teams to provide MRs in both
community pharmacies and ambulatory clinics could
improve the management of hypertension, type 2 diabetes
mellitus, and dyslipidemias.
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number of visits, PCNE MR category, method of communication
with patients and physicians, and clinical outcomes.
Nonpharmacological interventions included education in
lifestyle changes, medication use and disease; self-monitoring
of parameters; vitals assessment such as BP, capillary
glycemia, or cholesterol measurements; and adherence inter-
ventions. Pharmacological interventions consisted of pharma-
cists suggesting modifications to treatment in detected drug-
related problems or only in CVD risk problems.5–10
Two ambulatory settings were included. An ambulatory clinic
(AC) is defined as a primary care center where health care is
mostly provided by general practitioners but could also include
specialized outpatient clinics.15 Community pharmacies (CPs)
are legally approved establishments that supply prescription
and nonprescription medicines and may provide professional
pharmacy services and patient counselling while dispensing.16
Quality Assessment
The revised Cochrane risk-of-bias tool for randomized controlled
trials was used to identify the risk of bias. Studies were classified
as having low risk, high risk, or some concerns of bias.17
Statistical Analyses
Pairwise meta-analyses of the studies were performed for the
outcome measures whenever possible. These analyses were
conducted using the software Comprehensive Meta-Analysis
version 3 (Biostat).
The random effect model was used with the inverse of the
variance to obtain pooled effect sizes, and results were reported
with a 95% CI and P<0.05. The calculation of 95% prediction
intervals (PIs) was performed in preformatted sheets in Excel
with the method described by Borenstein and Higgins using
mean effect size and its variance (random effect weights),
degrees of freedom, and Tau2 (estimation measure of the true
effect size distribution) in log units (normal approximation).18,19
PIs allowmore informative inferences inmeta-analyses (eg, true
treatment effects that can be expected in future settings),
especially when there is large variation in the strength of the
effect (high heterogeneity between studies).14,18,19
For the meta-analyses of dichotomous data (therapeutic
goals), the odds ratio (OR) was calculated. For themeta-analyses
of continuous outcomes, the differences between baseline and
final valueswith the correspondingSDs reportedby the individual
studies (pre-post correlation of 0.999) were used.14
For articles that reported 95% CI as a measure of
uncertainty, SD was calculated using the size of the samples,
the length of the CI, and the value from Student t distribution.
When numeric data were insufficient to conduct the pooled
analysis, a request was sent to the author by email. If the
authors responded negatively or not at all, we excluded the
article from the analyses.18,19
The between-trial heterogeneity was assessed using the
inconsistency index value (I2 statistic) with ranges of <25%
(low), 25–50% (moderate), 50–75% (high) and >75% (very high)
heterogeneity. Sensitivity analyses were conducted together
with analyses for publication and other bias (funnel and
scatter plots, Failsafe N) to test the robustness of the results.
Subgroup analyses considering setting and components of
interventions were performed when possible.14
Results
Sixty-nine studies reported data that could be included in the
meta-analyses (Figure 1). One study was excluded from these
Table 1. Inclusion and Exclusion Criteria
Category Inclusion Criteria
Population Patients older than 18 years with hypertension, T2DM, or dyslipidemia as CVD risk factors
Setting Ambulatory care settings as ACs or CPs
Study design RCT or cluster RCT
Intervention Medication reviews provided by pharmacists describing the components of the intervention
Comparator Usual care
Outcomes Studies that include at least 1 of the outcomes of study. Outcomes were dichotomic as the control of hypertension; T2DM and
dyslipidemia as achievement of clinical targets defined in each study; and continuous as systolic blood pressure, diastolic
blood pressure, glycated hemoglobin, fasting glucose, total cholesterol, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, and triglycerides
Language of publication English or Spanish
Category Exclusion criteria
Missing data Studies that report incomplete values (as lacking uncertainty) when the authors could not provide this information when requested
ACs indicates ambulatory clinics; CPs, community pharmacies; CVD, cardiovascular disease; RCT, randomized controlled trial; T2DM, type 2 diabetes mellitus.
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analyses because it lacked uncertainty data (and the author
responded negatively). Forty-five of these studies were
undertaken in ACs and 24 in CPs. The total number of
patients was 11 743, with 11 644 included in the meta-
analyses. Of these, 8014 patients were in ACs and 3630 in
CPs, with a mean age of 607.2 years, and the percentage of
men in the included studies was 438.8%, without differ-
ences between subgroups (Table 2). The mean follow-up time
was 8.354.44 months, and there were 5.212.52 contacts
with patients in average. Most studies provided lifestyle and
disease education, and 23 studies considered the opinion of
each patient before changing pharmacotherapy. In 39 studies,
pharmacists only implemented changes in medications for
CVD risk (ignoring other medical conditions). In 48 studies,
pharmacists assessed vitals during the interviews and
provided self-monitoring education in 38 studies.
Risk of Bias
Sixty-one of the 69 studies included in the meta-analysis
presented low risk or some concerns about bias. The main
issues were the impossibility to blind patients to the
intervention and the lack of details in the randomization
process. Eight studies had a high risk of bias, mostly because
of indefinite randomization and the lack of blinded process in
the assessment of clinical outcomes. The effect of excluding
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Figure 1. PRISMA flowchart for systematic review and meta-analysis.12,13. c-RCT indicates cluster
randomized controlled trial; RCT, randomized controlled trial.
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high-risk articles from the analyses was explored for each
outcome.20–27 Table S2 presents individual risk-of-bias
analysis.
Clinical Outcomes and Components
Figures 2 through 4 and Tables 3 through 5 present clinical
outcomes overall and by individual setting. Figures S1 through
S8 contain additional forest plots for each clinical outcome
and Table S3 shows the effect of each individual component
and type of MR.
Hypertension
Table 3 presents pooled size effects for hypertension out-
comes. Mean follow-up time of the MR service was
8.494.99 months, with 5.282.59 patient visits. The
meta-analysis for overall BP control (31 studies; n=7031
patients) showed a statistically significant pooled OR of 2.73
(95% PI, 1.05–7.08) (Figure 2). Heterogeneity was high
(I2=71%) and the AC subgroup also had a significant PI.
Fifty-two studies (n=9935 patients) were included in the
analysis of systolic BP (SBP) (Figure S1). Heterogeneity was
very high (I2=99%) and resulted in significant PIs for the CP
subgroup but not for the AC subgroup or overall.
For diastolic BP (DBP) (49 studies; n=9526 patients)
heterogeneity was very high (I2=99%), and PIs were not
significant overall or in subgroups (Figure S2).
Excluding studies with a high risk of bias, small studies or
outliers resulted in similar results for hypertension outcomes
(Table 3).
Type 2 Diabetes Mellitus
For diabetes mellitus studies, mean follow-up time was
9.966.22 months, with 4.882.57 patient visits. The over-
all OR for achievement of T2DM control (12 studies; n=1805
patients) was 3.11 (95% PI, 1.48–6.52) (Figure 3). Only 1 CP
article reported this outcome, and the AC subgroup showed a
significant PI. Heterogeneity was moderate (I2=30%). No
article had a high risk of bias. Table 4 presents effect sizes for
T2DM outcomes.
A total of 3452 patients with T2DM from 25 studies were
included in the analysis of the differences in HbA1c levels
(Figure S3). There was very high heterogeneity (I2=99%),
which resulted in a nonsignificant PI. Subgroup analysis also
showed no significant PI. No study had a high risk of bias.
In the fasting glucose analysis (17 studies; n=2505
patients) there was very high heterogeneity (I2=99%) with
nonsignificant PI (Figure S4).
Sensitivity analyses showed no differences except for the
exclusion of 3 outliers in diabetes mellitus control, whichTa
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reduced heterogeneity to 0%, and 1 outlier in HbA1c, which
resulted in a significant PI overall (Table 4).
Dyslipidemias
Table 5 presents dyslipidemia outcomes. Mean follow-up time
was 9.016.31 months, with 5.582.87 patient visits.
Eleven studies (n=2012 patients) reported cholesterol goals
(Figure 4), finding a significant OR of 1.91 (95% PI, 1.05–
3.46), with moderate heterogeneity (I2=31%). AC had a
significant PI. There were no studies with a high risk of bias.
The analysis of total cholesterol had very high heterogeneity
(I2=99%) resulting in a nonsignificant PI (Figure S5). There was a
significant difference between subgroups (Q=7.91, P=0.005),
with ACs having a larger reduction in TC levels than CPs.
Very high heterogeneity (I2=99%) was found in the low-
density lipoprotein cholesterol analysis, with a significant PI in
the CP subgroup only (Figure S6). A statistical difference was
observed between subgroups (Q=9.62, P=0.002) with a larger
effect in ACs. CP analysis included 5 studies versus 15 in the
AC subgroup.
For high-density lipoprotein cholesterol (20 studies; n=2804
patients), there was very high heterogeneity (I2=99%), which led
to a nonsignificant PI (Figure S7). There was a significant
difference between subgroups (Q=5.25, P=0.022), with a larger
effect in ACs versus CPs, but none had statistical significance.
For triglyceride levels (23 studies; n=3185), a nonsignifi-
cant PI was observed with very high heterogeneity (I2=99%)
(Figure S8).
Excluding small studies or an outlier reduced heterogeneity
to 0% and produced significant PI in the control of total
cholesterol (Table 5).
Discussion
To our knowledge, this is the first meta-analysis for MRs that
includes a high number of CVD outcomes and uses PIs to
account for high heterogeneity. The inclusion of control of
Group by
Setting
Study name Statistics for each study Controlled / Total Odds ratio and 95% CI
Odds Lower Upper Med Usual Relative 
ratio limit limit Z-Value p-Value Review Care weight
Ambulatory Clinic Aguiar 2016 3.69 1.2 11.1 2.33 0.02 15 / 36 6 / 37 2.7
Ambulatory Clinic Albsoul-Younes 2011 2.07 1.2 3.7 2.51 0.01 104 / 130 81 / 123 4.7
Ambulatory Clinic Bogden 1998 5.05 2.0 12.7 3.45 0.00 27 / 49 9 / 46 3.3
Ambulatory Clinic Borenstein 2003 1.97 1.1 3.5 2.34 0.02 59 / 98 43 / 99 4.7
Ambulatory Clinic Carter 2008 4.16 2.7 6.3 6.70 0.00 123 / 192 63 / 210 5.4
Ambulatory Clinic Carter 2009 4.07 2.7 6.2 6.60 0.00 122 / 192 63 / 210 5.4
Ambulatory Clinic Chan 2012 1.56 0.5 5.3 0.71 0.47 7 / 51 5 / 54 2.4
Ambulatory Clinic Ebid 2014 3.92 2.3 6.8 4.92 0.00 99 / 125 69 / 140 4.8
Ambulatory Clinic Green 2008 2.31 1.6 3.3 4.41 0.00 120 / 237 76 / 247 5.6
Ambulatory Clinic Hedegaard 2015 1.20 0.8 1.8 0.86 0.39 63 / 167 72 / 215 5.4
Ambulatory Clinic Hunt 2008 2.09 1.3 3.4 2.98 0.00 88 / 142 57 / 130 5.1
Ambulatory Clinic Jacobs 2012 1.38 0.7 2.8 0.90 0.37 29 / 57 30 / 70 4.1
Ambulatory Clinic Jarab 2012 4.69 2.3 9.6 4.23 0.00 62 / 77 37 / 79 4.1
Ambulatory Clinic Korcegez 2017 2.92 1.4 5.9 2.94 0.00 59 / 75 43 / 77 4.1
Ambulatory Clinic Morgado 2011 2.54 1.4 4.5 3.18 0.00 62 / 98 40 / 99 4.7
Ambulatory Clinic Obreli-Neto 2011 14.43 7.0 29.8 7.21 0.00 84 / 97 30 / 97 4.0
Ambulatory Clinic Polgreen 2015 1.61 1.2 2.2 2.83 0.00 244 / 401 110 / 224 5.7
Ambulatory Clinic Scott 2006 4.40 2.1 9.5 3.81 0.00 50 / 64 30 / 67 3.9
Ambulatory Clinic Shao 2017 2.21 1.2 4.0 2.66 0.01 71 / 100 52 / 99 4.6
Ambulatory Clinic Simpson 2011 2.00 1.2 3.4 2.50 0.01 48 / 129 30 / 131 4.8
Ambulatory Clinic Sookaneknun 2004 1.46 0.9 2.5 1.39 0.16 78 / 118 67 / 117 4.9
Ambulatory Clinic Taylor 2003 28.88 5.5 152.0 3.97 0.00 22 / 24 8 / 29 1.6
Ambulatory Clinic Tobari 2010 1.28 0.6 2.6 0.71 0.48 34 / 64 30 / 64 4.2
Ambulatory Clinic 2.67 2.1 3.4 8.10 0.00 1670 / 2723 1051 / 2664
Community Pharmacy Amariles 2012 1.99 1.5 2.7 4.49 0.00 187 / 356 128 / 358 20.7
Community Pharmacy Garcao 2002 29.71 6.9 128.2 4.55 0.00 24 / 31 3 / 29 6.2
Community Pharmacy Krass 2007 1.75 1.0 3.2 1.85 0.06 48 / 87 38 / 92 15.9
Community Pharmacy Park 1996 2.45 0.8 7.9 1.51 0.13 12 / 23 8 / 26 8.4
Community Pharmacy Planas 2009 12.92 1.5 113.8 2.31 0.02 12 / 25 1 / 15 3.3
Community Pharmacy Robinson 2010 3.43 1.6 7.2 3.25 0.00 39 / 78 14 / 62 13.5
Community Pharmacy Torres 2009 3.47 2.3 5.3 5.66 0.00 123 / 183 68 / 183 18.6
Community Pharmacy Zillich 2005 1.74 0.8 3.7 1.47 0.14 27 / 64 18 / 61 13.5
Community Pharmacy 2.92 1.9 4.5 4.96 0.00 472 / 847 278 / 826
Overall 2.73 2.2 3.4 9.49 0.00 2142 / 3570 1329 / 3490
0.01 0.1 1 10 100
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Figure 2. Meta-analysis of patients reaching blood pressure control with medication reviews or usual care. Values in odds ratios with 95% CIs.
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Study name Statistics for each study Controlled / Total Odds ratio and 95% CI
Odds Lower Upper Med Usual Relative 
ratio limit limit Z-Value p-Value Review Care weight
Aguiar 2016 7.20 0.8 63.2 1.78 0.07 6 / 36 1 / 37 2.0
Al Mazroui 2009 1.94 1.1 3.3 2.42 0.02 53 / 117 35 / 117 16.5
Chan 2012 3.31 0.3 32.9 1.02 0.31 3 / 51 1 / 54 1.8
Jacobs 2012 2.00 0.9 4.5 1.68 0.09 19 / 55 14 / 67 10.3
Jameson 2010 2.94 1.3 6.6 2.63 0.01 35 / 52 21 / 51 10.4
Jarab 2012 1.89 0.8 4.3 1.50 0.13 18 / 77 11 / 79 10.0
Korcegez 2017 15.89 2.0 124.8 2.63 0.01 13 / 76 1 / 78 2.2
Obreli-Neto 2011 23.38 3.1 178.6 3.04 0.00 19 / 97 1 / 97 2.3
Scott 2006 3.67 1.8 7.6 3.53 0.00 43 / 64 24 / 67 12.0
Shao 2017 3.50 1.9 6.4 4.06 0.00 76 / 100 47 / 99 14.7
Taylor 2003 26.40 2.7 262.7 2.79 0.01 12 / 13 5 / 16 1.8
Chung 2014 3.15 1.8 5.5 4.03 0.00 57 / 120 27 / 121 15.9
3.11 2.3 4.3 6.97 0.00 354 / 858 188 / 883
0.01 0.1 1 10 100
Favours Usual Care Favours Med Review
Achievement of type-2 diabetes control
45
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Figure 3. Meta-analysis of patients with type 2 diabetes mellitus reaching glycated hemoglobin <7% with medication reviews or usual care.
Values in odds ratios with 95% CIs.
Group by
Setting
Study name Statistics for each study Controlled / Total Odds ratio and 95% CI
Odds Lower Upper Med Usual Relative 
ratio limit limit Z-Value p-Value Review Care weight
Ambulatory Clinic Bogden 1997 2.74 1.1 6.8 2.18 0.03 20 / 47 10 / 47 11.4
Ambulatory Clinic Chan 2012 2.68 0.8 9.3 1.55 0.12 9 / 51 4 / 54 6.8
Ambulatory Clinic Jacobs 2012 1.33 0.6 3.0 0.69 0.49 32 / 52 24 / 44 13.4
Ambulatory Clinic Jarab 2012 2.75 1.4 5.3 3.02 0.00 42 / 77 24 / 79 17.9
Ambulatory Clinic Obreli-Neto 2011 2.32 1.2 4.4 2.53 0.01 78 / 97 62 / 97 18.1
Ambulatory Clinic Scott 2006 2.22 1.0 4.8 2.05 0.04 25 / 64 15 / 67 14.7
Ambulatory Clinic Tahaine 2011 2.89 1.4 6.0 2.83 0.00 47 / 73 20 / 52 15.4
Ambulatory Clinic Taylor 2003 50.40 5.3 481.9 3.40 0.00 14 / 19 1 / 19 2.3
Ambulatory Clinic 2.52 1.8 3.6 5.18 0.00 267 / 480 160 / 459
Community Pharmacy Amariles 2012 1.64 1.2 2.2 3.29 0.00 201 / 356 158 / 358 79.0
Community Pharmacy Nola 2000 2.59 0.7 10.1 1.37 0.17 8 / 25 4 / 26 3.7
Community Pharmacy Villeneuve 2010 1.43 0.8 2.7 1.11 0.27 87 / 108 87 / 117 17.3
Community Pharmacy 1.63 1.3 2.1 3.65 0.00 296 / 489 249 / 501
Overall 1.91 1.5 2.4 6.03 0.00 563 / 969 409 / 960
0.01 0.1 1 10 100
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Achievement of Total Cholesterol control
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Figure 4. Meta-analysis of patients reaching cholesterol control with medication reviews or usual care. Values in odds ratios with 95% CIs.
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hypertension, T2DM, and dyslipidemia and continuous clin-
ical outcomes allowed exploration of a multidimensional
effect of the provision of MR by pharmacists. We included a
high number of studies and accounted for multiple
components of the intervention, exploring the effect of
possible bias.
Settings presented significant differences in some out-
comes, with the AC subgroup having larger effect sizes in
cholesterol values and DBP. This subgroup had significant
increases in the achievement of T2DM and TC goals with
moderate heterogeneity. Continuous outcomes had high
heterogeneity and nonsignificant PIs.
In contrast with community pharmacists, AC pharmacists
could directly be part of clinical teams, which may help to
increase the acceptance of interventions from physicians,
thus increasing the impact of MR.9 This assumption could
not be tested since only a small number of studies included
acceptance rate. The AC group included more patients
(almost twice), longer follow-up times (37.3 months
difference), and more studies in all outcomes than the CP
subgroup. All of these elements could increase effects sizes
and heterogeneity at the same time.14 More studies were
undertaken in the AC setting, some with high effects
(outliers); however, we found no differences in magnitude
and significance of effects when removed from the
analyses.
In CPs there were significant decreases in low-density
lipoprotein and SBP values. CP studies tended to be shorter
and smaller than AC studies. All CP effects were more
affected than ACs when accounting for a high risk of bias and
publication bias, with fewer reporting the number of outcomes
per study. The lower number of patients within each study
could have lowered heterogeneity (increasing statistical
significance) and effect sizes in almost all outcomes.10,14
MR classification had significant differences between types
2 and 3, with advanced MRs providing larger effects in DBP,
HbA1c, and lipids, but this significance is limited because of a
small number of pairwise comparisons, and no study with type
1 MR classification resulted from the inclusion criteria
(Table S3).11,14 Most of the individual components of the
MR service did not have significant effects on outcomes
(Table S3). Assessment of BP during visits increased the
effect in control of BP and SBP, as patients tend to improve
compliance when they are tightly monitored.1–3
Table 3. Pooled Analysis of Hypertension Outcomes
Outcome Analysis
Studies (No.
of Patients) Effect Size 95% CI I2, % 95% PI
BP control (OR) Overall 31 (7031) 2.73 2.20–3.36* 71 1.05–7.08*
Setting AC 23 (5332) 2.67 2.11–3.39* 74 0.97–7.49
CP 8 (1699) 2.92 1.91–4.46* 66 0.86–9.92
Sample size Excluding N <10026,32,35,45,50,84 25 (6635) 2.43 2.02–2.93* 70 1.04–5.69*
RoB Excluding high35,36,50,51,82 26 (6324) 2.74 2.18–3.44* 73 1.02–7.39*
Outliers Excluding OR>2026,84 29 (6896) 2.51 2.11–3.07* 67 1.08–5.82*
SBP, mm Hg Overall 52 (9935) 8.50 9.66 to 7.34* 99 19.0 to 1.68
Setting AC 33 (6816) 8.34 10.1 to 6.61* 99 18.8 to 2.02
CP 19 (3119) 8.64 10.2 to 7.07* 99 16.0 to 1.26*
Sample size Excluding N <10021,26,27,30,32,33,35,37 36 (8887) 7.53 9.17 to 5.89* 99 17.8 to 2.76
RoB Excluding high21,35,36,39,48,50,51 45 (9144) 7.94 9.45 to 6.42* 99 18.5 to 2.57
Outliers Excluding >20 mm Hg
decrease in SBP30,35,73
49 (9640) 7.54 8.72 to 6.54* 99 15.3 to 0.27*
DBP, mm Hg Overall 49 (9526) 3.68 4.45 to 2.92* 99 9.56 to 2.20
Setting AC 32 (6619) 4.53 5.75 to 3.32* 99 11.8 to 2.74
CP 17 (2907) 3.13 4.11 to 2.14* 99 7.60, 1.34
Sample size Excluding N <10021,26,27,30,32,33,37,42 34 (8518) 3.85 4.85 to 2.85* 99 9.98 to 2.28
RoB Excluding high21,36,48,50,82 44 (8972) 3.78 4.65 to 2.91* 99 9.74 to 2.18
Outliers Excluding >10 mm Hg
decrease in DBP50,73
47 (9237) 3.72 4.50 to 2.94* 99 9.24 to 1.80
AC indicates ambulatory clinic; BP, blood pressure; CP, community pharmacy; DBP, diastolic blood pressure; N, total number of patients; OR, odds ratio; PI, prediction interval; RoB, risk of
bias; SBP, systolic blood pressure.
*Statistical significance.
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Decreasing cholesterol or BP values would be expected to
happen faster and to require fewer visits than improving
diabetes mellitus outcomes, but we found no differences in
follow-up times or the number of visits for the included
studies or in regard to the observed effects.1–3 In hyperten-
sion, a significant increase overall in achievement of BP goals
was found. Analyses show nonsignificant decreases in SBP
and DBP (only CP achieved PI significance in SBP) but with
high heterogeneity. Excluding small studies in the SBP
analysis had no effect in the AC subgroup but decreased
the effect in CPs and prevented significant PIs, which,
together with an asymmetric funnel plot, suggested that
there was a risk of publication bias in the CP subgroup
(excluding outliers produced the same effect as they were
mostly in CPs).14 The small effect in DBP could be explained
by the fact that most included patients were older adults, who
often have isolated systolic hypertension.2,3
In T2DM, an overall significant increase in achieving HbA1c
goals was observed. Only 1 CP study reported this outcome
despite most studies reporting HbA1c percentages and being
a key outcome, which prevented subgroup analysis.9 In
dyslipidemia outcomes, the control of total cholesterol
increased significantly overall and in ACs even while removing
outliers or small studies, but not in continuous variables
(except for low-density lipoprotein cholesterol in CP with a low
number of studies) as heterogeneity was high.
Previous reviews reported significant reductions in SBP,
DBP, HbA1c, and cholesterol values, and our analysis reported
a similar magnitude in clinical changes.6–10 However, we
found that at a larger number of studies and when accounting
for heterogeneity, statistical significance was lost in most
continuous outcomes (as shown by nonsignificant PI). Nev-
ertheless, our results support a significant effect in the control
of these cardiovascular risk diseases by pharmacist-led MRs,
even when accounting for high heterogeneity.
There are only a limited number of studies that measure the
impact of MR services by other health professionals. Nurses
generally show lower effects than pharmacist-ledMRs in similar
outcomes, but interventions that included both pharmacists
and nurses seemed to provide better outcomes.6–10,90–95
Previous evidence has suggested that heterogeneity in
pharmaceutical care studies could be accounted for by some
major causes such as differences in sampling, patient
demographic and clinical characteristics, differences in inter-
vention components, and fidelity of the intervention.9,10,96,97
We found that most studies had similar patient characteristics
such as age, sex percentage, and baseline health conditions
of patients. Interestingly, excluding outliers had no effect on
the magnitude of point estimate or heterogeneity.
The effects of individual components of the MR service
were examined, but the description of interventions was both
vague and varied greatly. Most studies did not include key
points such as acceptance rate for interventions and fidelity
of the pharmacists to provide MR, which could have effects on
outcomes.96,97 The interaction between physicians and phar-
macists was poorly described in many studies, therefore
Table 4. Pooled Analysis of T2DM Outcomes
Outcome Analysis Studies (Patients) Effect Size 95% CI I2, % 95% PI
T2DM control (OR) Overall 12 (1805) 3.11 2.26–4.27* 30 1.48–6.52*
Setting Excluding CP 11 (1564) 3.18 2.18–4.65* 36 1.27–8.00*
Sample size Excluding N <10045,84 10 (1679) 2.89 2.16–3.87* 22 1.58–5.27*
Outliers Excluding OR >1569,73,84 9 (1406) 2.71 2.11–3.47* 0 2.01–3.65*
HbA1c, % Overall 25 (3452) 0.81 0.99 to 0.64* 99 1.78 to 0.15
Setting AC 18 (2569) 0.93 1.17 to 0.69* 99 2.05 to 0.19
CP 7 (833) 0.69 0.94 to 0.45* 99 1.57 to 0.19
Sample size Excluding N <10024,27,33,39,44,45,56,57 17 (2802) 0.99 1.25 to 0.74* 99 2.16 to 0.18
Outliers Excluding >1.5% decrease46 24 (3218) 0.84 0.97 to 0.70* 99 1.51 to 0.13*
Fasting glucose,
mg/dL
Overall 17 (2505) 28.8 38.1, 19.6* 99 70.9, 13.2
Setting AC 13 (1790) 30.9 41.0 to 20.9* 99 73.0 to 11.2
CP 4 (715) 18.2 41.1 to 4.50 99 13.0 to 94.0
Sample size Excluding N <10033,44,48,61,75 12 (2146) 27.8 37.1 to 18.5* 99 65.8 to 10.2
RoB Excluding high48 16 (2442) 28.3 37.8 to 18.8* 99 70.7 to 14.1
Outliers Excluding >50 mg/dL decrease23,68,75,88 13 (1939) 20.3 27.9 to 12.7* 99 51.8 to 11.2
AC indicates ambulatory clinic; CP, community pharmacy; HbA1c, glycated hemoglobin; OR, odds ratio; PI, prediction interval; RoB, risk of bias; T2DM, type 2 diabetes mellitus.
*Statistical significance.
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sensitivity analysis could not be performed. It would be
optimal when generating evidence to have and use a
standardized intervention that clearly defines the components
and characteristics of the intervention, ie, dose and fidelity so
that this source of heterogeneity could be ameliorated.96,97
Intermediate and advanced MR services seem to provide
benefits in controlling cardiovascular risk diseases as a result
of many factors such as resolution of drug-related problems,
increase in medication adherence, simplification of therapies,
and reduction of clinical inertia (common in cardiovascular
conditions).5–11 We believe that the increase in control of
hypertension, T2DM, and dyslipidemias of pharmacist-led MR
and its positive effects in most clinical outcomes support the
implementation of this service, but more evidence is neces-
sary regarding the in-depth description of components to
optimize its effects.
Study Limitations
This study has several limitations. Moderate to high hetero-
geneity was observed, which represented a difficulty in
establishing the true impact of MR. Individual effects of
components of the MR interventions could not be adequately
compared. Because of large variability in the number of
Table 5. Pooled Analysis of Dyslipidemia Outcomes
Outcome Analysis Studies (Patients) Effect Size 95% CI I2, % 95% PI
TC control (OR) Overall 11 (2012) 1.91 1.55–2.35* 31 1.05–3.46*
Setting AC 8 (1022) 2.52 1.78–3.58* 26 1.18–5.40*
CP 3 (990) 1.63 1.25–2.12* 0 0.29–8.97
Sample size Excluding N <10031,49,84 8 (1814) 1.87 1.68–2.90* 0 1.01–3.50*
Outliers Excluding OR >1084 10 (1959) 1.92 1.58–2.34* 0 1.53–2.42*
TC, mg/dL Overall 24 (3851) 14.3 18.2 to 10.5* 99 36.3 to 7.63
Setting AC 17 (2439) 18.1 23.2 to 12.9* 99 41.6 to 5.52
CP 7 (1412) 9.73 15.5 to 3.99* 99 29.2 to 9.79
Sample size Excluding N <10031,33,34,48,49,61,75 17 (3393) 14.7 19.3 to 10.1* 99 35.9 to 6.42
RoB Excluding high48 23 (3788) 14.4 18.3 to 10.5* 99 36.1 to 7.28
Outliers Excluding >30 mg/dL decrease46,49,68 21 (3367) 13.3 16.7 to 10.0* 99 29.7 to 3.06
LDL-C, mg/dL Overall 20 (2576) 10.3 12.1 to 8.57* 99 23.9 to 3.31
Setting AC 15 (2021) 15.3 18.9 to 11.7* 99 31.0 to 0.40
CP 5 (555) 8.80 10.8 to 6.82* 96 16.4 to 1.17*
Sample size Excluding N <10024,31,33,45,48,61,75 13 (2103) 15.6 18.7 to 12.4* 99 28.6 to 2.52*
RoB Excluding high48 19 (2513) 13.7 16.6 to 10.7* 99 27.7 to 0.38
Outliers Excluding >25 mg/dL decrease46,75 18 (2279) 12.1 14.9 to 9.37* 99 24.9 to 0.64
HDL-C, mg/dL Overall 20 (2804) 0.90 0.40–1.40* 99 10.2 to 12.0
Setting AC 16 (2327) 4.07 1.66–6.49* 99 6.80 to 15.0
CP 4 (477) 0.76 0.26–1.27* 99 1.49 to 3.02
Sample size Excluding N <10031,33,48,61,75 15 (2483) 2.87 0.58–5.17* 99 7.21 to 13.0
RoB Excluding high48 19 (2741) 3.26 0.85–5.66* 99 8.30 to 14.8
Outliers Excluding >10 mg/dL increase73,75 18 (2376) 2.72 1.65–3.78* 99 2.26 to 7.70
Triglycerides,
mg/dL
Overall 23 (3185) 29.7 36.4 to 23.0* 99 64.2 to 4.78
Setting AC 16 (2327) 34.8 43.8 to 25.8* 99 74.4 to 4.83
CP 7 (858) 23.4 33.4 to 13.4* 99 57.7 to 11.0
Sample size Excluding N <10031,33,34,48,61,75 17 (2821) 30.2 38.3 to 22.1* 99 66.8 to 6.40
RoB Excluding high48 22 (3122) 30.5 37.5 to 23.5* 99 65.1 to 4.08
Outliers Excluding >60 mg/dL decrease34,48,68,86 19 (2782) 24.3 31.1 to 17.5* 99 56.1 to 7.48
AC indicates ambulatory clinic; CP, community pharmacy; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; PI, prediction interval;
RoB, risk of bias; TC, total cholesterol.
*Statistical significance.
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reported components in many studies, combined effects
meta-regressions could not be performed, therefore paired
analyses using means and P values for significance had to be
used. These results could be biased by the combined
accumulation of type I errors for the large number of studies,
thus its results should be interpreted with caution.14 There
could be some risk of bias as a result of the exclusion of
languages other than English and Spanish, with differences in
cultural and healthcare system organization.
Conclusions
There is evidence to conclude that MRs provided by
pharmacists may improve control of BP, cholesterol, and
T2DM as significant effects sizes and PIs were found overall.
We could not conclude that MR was better than usual care in
most continuous clinical outcomes. Although effect sizes
were positive with significant CIs for all analyses and settings,
PI lacked significance in these outcomes. ACs had significant
effects in the achievement of control of diabetes mellitus and
high cholesterol, while CPs had significant decreases in SBP
and low-density lipoprotein cholesterol values, but larger
studies are needed to further explore these differences.
Advanced MRs in ACs could have larger effects in diabetes
mellitus and cholesterol outcomes, but more evidence is
needed. To ensure that there is optimization of research
resources and for healthcare systems to adopt MR as usual
practice, international standards should be set for the
evaluation of MR services including defining in detail the
target population and the MR intervention.
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Table S1. Complete search strategies. 
Database Search details Results 
MEDLINE 
(PubMed) 
((((pharmaceutical services[MeSH Terms]) OR (pharmacists) OR 
"medication review" OR "pharmaceutical care") AND 
((hypertension[MeSH Terms]) OR (diabetes mellitus, Type 2[MeSH 
Terms]) OR (cardiovascular) OR (cholesterol, LDL[MeSH Terms]) OR 
"blood pressure" OR diabetes OR hypertension))) AND ((primary OR 
ambulatory OR clinic OR outpatient OR pharmacies OR community)) 
3161 
Web of Science 
(without 
MEDLINE) 
TI= ((pharmacists OR "pharmaceutical care" OR "medication review" 
OR "pharmaceutical services") AND (community OR ambulatory OR 
primary OR clinic) AND (cardiovascular OR hypertension OR diabetes 
OR cholesterol)) 
257 
Embase (Ovid) 
(without 
MEDLINE) 
((pharmacist or "medication review" or "pharmaceutical services" or 
"pharmaceutical care" or "pharmacy care" or pharmacists) and 
(community or clinic or primary) and (cardiovascular or hypertension 
or diabetes or cholesterol)).mp. 
331 
Cochrane 
CENTRAL Library 
((pharmacists OR "pharmaceutical care" OR "medication review" OR 
"pharmaceutical services") AND (community OR ambulatory OR 
primary OR clinic) AND (cardiovascular OR hypertension OR diabetes 
OR cholesterol)) 
1091 
The Cumulative 
Index to Nursing 
and Allied Health 
Literature 
(CINAHL) 
((pharmacists OR "pharmaceutical care" OR "medication review" OR 
"pharmaceutical services")) AND ((community OR ambulatory OR 
primary OR clinic)) AND ((cardiovascular OR hypertension OR 
diabetes OR cholesterol)) 
327 
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Table S2. Results of the revised Cochrane risk of bias tool for randomized controlled trials and cluster randomized trials. 
Study Name Random 
Individual allocation 
(clusters) 
Deviations from 
the intervention 
Missing 
data 
Measure of 
outcome 
Selection 
report 
Others Bias 
Abuloha et al 20161 L  L L L L L LOW 
Aguiar et al 20162 L  L L L L C LOW 
Al Mazroui et al 20093 C  L L C L L CONCERNS 
Albsoul-Younes et al 20114 L  L L L L L LOW 
Amariles et al 20125 L L L L L L L LOW 
Azevedo et al 20176 C  L L H L L HIGH 
Bajorek et al 20167 C C H L C L L HIGH 
Basheti et al 20168 L  L L C L L CONCERNS 
Bogden et al 19979 C L L L C L L CONCERNS 
Bogden et al 199810 H L L L L L L HIGH 
Borenstein et al 200311 C  L L H L L HIGH 
Carter et al 200812 L C L L C L L CONCERNS 
Carter et al 200913 L L L L L L L LOW 
Chan et al 201214 L  L L L L L LOW 
Chen et al 201615 L  L L L L L LOW 
Choe et al 200516 C  L L L C L CONCERNS 
Chung et al 201417 C  L L C L L CONCERNS 
Clifford et al 200218 L  L L C L L LOW 
Clifford et al 200519 C  L L C L L CONCERNS 
de Castro et al 201520 L  L L C L L LOW 
Doucette et al 200921 C  L L C L L CONCERNS 
Ebid et al 201422 C  L L L L L LOW 
Firminho et al 201523 L  L L C L L CONCERNS 
Fornos et al 200624 L  L L C L L CONCERNS 
Garcao et al 200225 C  L L C L L CONCERNS 
Green et al 200826 L  L L L L L LOW 
Hammad et al 201127 L  L L L L L LOW 
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Hedegaard et al 201528 L  L L L L L LOW 
Hunt et al 200829 L  L L L L C LOW 
Jacobs et al 201230 L  L L L L L LOW 
Jahangard-Rafsanjani et al 201431 L  L L L L L LOW 
Jameson et al 201032 L  L L L L L LOW 
Jarab et al 201233 L  L L C C L CONCERNS 
Kjeldsen et al 201434 C  L L C L L CONCERNS 
Korcegez et al 201735 L  L L L L L LOW 
Krass et al 200736 C C L L C L L CONCERNS 
Lee et al 200937 L  L L L L L LOW 
Lugo De Ortellado et al 200838 C  L L C L L CONCERNS 
Morgado et al 201139 L  L L L L L LOW 
Mourao et al 201340 L  L L C L L CONCERNS 
Nola et al 200041 L  L L L L L LOW 
Obreli-Neto et al 201142 L  L L L L L LOW 
Okamoto et al 200143 L  L L C L C CONCERNS 
Oparah 200944 L  L H U H L HIGH 
Park et al 199645 C  L L C L L CONCERNS 
Paulo et al 201646 C  L L C L L CONCERNS 
Paulos et al 200547 C  L L C L L CONCERNS 
Planas et al 200948 L  L L C H L HIGH 
Plaster et al 201249 L  L L L L L LOW 
Polgreen et al 201550 L  L L L L L LOW 
Robinson et al 201051 C C L L L L L HIGH 
Rothman et al 200552 L  L L L L L LOW 
Sanchez-Guerra et al 201853 L  L L L L L LOW 
Scott et al 200654 L  L L C L L CONCERNS 
Shao et al 201755 L  L L L L L LOW 
Simpson et al 201156 L  L L L L L LOW 
Skowron et al 201057 C C L L C L L CONCERNS 
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Sookaneknun et al 200458 L  L L H L L HIGH 
Stewart et al 201459 L C L L C L L CONCERNS 
Tahaine et al 201160 L  L L L L L LOW 
Taylor et al 200361 C  L L C L L CONCERNS 
Taylor et al 201662 C C L L L L L HIGH 
Tobari et al 201063 L  L L C L L CONCERNS 
Torres et al 200964 L L L L C L L CONCERNS 
Villa et al 200965 C  L L L L L CONCERNS 
Villeneuve et al 201066 L L L L C L L CONCERNS 
Wal et al 201367 L  L L C C L CONCERNS 
Wang et al 201168 L  L L L L L LOW 
Wishah et al 201469 L  L L L L L LOW 
Zillich et al 200570 L C L L C L L CONCERNS 
 
C: some concerns; H: high risk; L: low risk. 
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Table S3. Analysis of the impact of settings, type of MR and components in all outcomes. 
*: statistical significance; †: comparison made with 1 or 2 studies; All DRP: intervention in all drug related problems 
found; BP: blood pressure; Ed: education; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein cholesterol; LDL: 
Low-density lipoprotein cholesterol; MR: Pharmaceutical Care Network Europe Medication review category; N/A: no 
studies to compare; Pat: patient; Phys: physician;  Self: self-monitoring; T2D: type 2 diabetes; TC: total cholesterol; TG: 
triglycerides; v/mo: visits per month. 
 
  
Components BP Goal T2D Goal TC Goal SBP DBP HbA1c FG TC LDL-C HDL-C TG 
Type of 
MR 
2 2.92 N/A 2.12 -8.52 -2.68 -0.62 -10.7 -8.1 -9.15 1.19 -23.4 
3 2.68 N/A 2.52 -8.41 -4.65 -0.94 -31.6 -19 -14.8 4.21 -34.8 
p value 0.73 N/A 0.58 0.92 0.01* 0.03* 0.04* 0.01* 0.01* 0.02* 0.11 
Specialist 
Phys 
Y 2.23 2.71 N/A -6.38 -4.24 -0.82 -35.9 -25 -15.7 3.09 -22.4 
N 2.82 3.67 N/A -8.97 -4.61 -0.97 -29.4 -17 -15.2 4.3 -34.3 
p value 0.40 0.44 N/A 0.15 0.81 0.62 0.42 0.12 0.94 0.48 0.62 
Follow-up 
time 
≤ 6 mo 2.84 3.5 2.82 -8.35 -3.97 -0.79 -32.5 -15 -15.3 4.24 -29.5 
> 6 mo 2.62 3.05 1.84 -8.62 -4.16 -0.18 -21.5 -15 -12 2.64 -36.1 
p value 0.70 0.78 0.12 0.84 0.83 0.50 0.30 0.96 0.32 0.50 0.50 
Number 
of visits 
≤ 1v/mo 2.32 3.15 3.32 -8.42 -3.93 -0.94 -32.2 -15 -16.7 6.64 -34.7 
> 1v/mo 2.96 3.18 2.11 -8.56 -4.31 -0.84 -25 -15 -12.7 2.49 -28.6 
p value 0.23 0.98 0.04* 0.92 0.68 0.56 0.55 0.94 0.42 0.06 0.45 
Disease Ed 
Y 2.63 3.09 2.24 -8.03 -3.89 -0.86 -29.6 -15 -14.5 3.85 -34.4 
N 2.97 3.67 2.57 -10.3 -4.75 -0.84 -2 -15 -6.89 0.6 -22.4 
p value 0.57 0.67† 0.62 0.25 0.27 0.98† 0.01† 0.95 0.01† 0.01† 0.01† 
Self  
Y 2.88 3.09 1.84 -8.22 -4.12 -0.86 -29.3 -15 -14 4.25 -34.2 
N 2.54 3.67 2.85 -8.93 -3.96 -0.89 -23.5 -15 -13.2 2.41 -8 
p value 0.63 0.67† 0.09 0.63 0.85 0.86 0.58 0.93 0.81 0.29 0.72 
Lifestyle 
Ed 
Y 2.66 N/A 2.33 -8.43 -3.97 -0.86 N/A -15 -14.2 3.7 -32.4 
N 3.3 N/A 2.74 -9.43 -5.01 -0.85 N/A -18 -5 0.2 -30 
p value 0.48† N/A 0.74† 0.65 0.43 0.98† N/A 0.80† 0.01† 0.01† 0.01† 
All DRP 
Y 3.93 4.98 2.25 -9.58 -4.16 -0.82 -27.5 -16 -13.3 3.76 -32.6 
N 2.22 2.87 2.63 -7.19 -3.91 -0.9 -28.3 -15 -14.1 3.28 -16 
p value 0.01* 0.23 0.58 0.10 0.78 0.69 0.91 0.86 0.78 0.81 0.87 
Pat goals 
Y 2.93 5.85 1.7 -9.49 -4.09 -0.7 -22.5 -13 -12.1 4.3 -31.6 
N 2.62 2.91 2.73 -7.77 -4.03 -0.94 -31.9 -17 -14.9 2.88 -30.2 
p value 0.62 0.31 0.02* 0.24 0.94 0.12 0.31 0.23 0.40 0.44 0.18 
Vitals 
assess 
Y 2.76 5.85 2.3 -9.49 -4.15 -0.75 -23.5 -13 -13.1 3.64 -39.5 
N 2.65 2.91 2.62 -4.92 -3.74 -0.98 -33 -22 -14.9 3.3 -26.8 
p value 0.97 0.31 0.71 0.01* 0.72 0.21 0.31 0.01* 0.64 0.85 0.65 
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Figure S1. Raw mean difference on Systolic Blood Pressure in millimetres of mercury.  
CI: confidence interval. 
  
Group by
Setting
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Standard Lower Upper Med Usual Relative Relative 
in means error limit limit Z-Value p-Value Review Care weight weight
Ambulatory Clinic Aguiar 2016 -8.10 0.2 -8.5 -7.7 -41.4 0.00 36 37 3.1
Ambulatory Clinic Al Mazroui 2009 -3.20 0.8 -4.7 -1.7 -4.2 0.00 117 117 3.0
Ambulatory Clinic Albsoul-Younes 2011 -5.50 0.1 -5.7 -5.3 -58.2 0.00 130 123 3.1
Ambulatory Clinic Azevedo 2017 -17.20 0.9 -18.9 -15.5 -19.8 0.00 33 30 3.0
Ambulatory Clinic Bogden 1998 -12.00 0.8 -13.6 -10.4 -15.0 0.00 49 46 3.0
Ambulatory Clinic Borenstein 2003 -11.00 0.1 -11.3 -10.7 -84.4 0.00 98 99 3.1
Ambulatory Clinic Carter 2008 -11.60 0.5 -12.6 -10.6 -22.2 0.00 101 78 3.0
Ambulatory Clinic Carter 2009 -13.90 0.5 -14.9 -12.9 -27.6 0.00 192 210 3.0
Ambulatory Clinic Chan 2012 -3.30 0.2 -3.7 -2.9 -16.5 0.00 51 54 3.1
Ambulatory Clinic Clifford 2005 -7.00 1.1 -9.1 -4.9 -6.6 0.00 92 88 2.9
Ambulatory Clinic de Castro 2015 -5.00 1.2 -7.4 -2.6 -4.1 0.00 30 34 2.9
Ambulatory Clinic Ebid 2014 -5.90 0.1 -6.2 -5.6 -41.3 0.00 140 140 3.1
Ambulatory Clinic Firminho 2015 -10.50 1.0 -12.4 -8.6 -10.8 0.00 26 30 3.0
Ambulatory Clinic Green 2008 -9.30 0.1 -9.4 -9.2 -165.7 0.00 237 247 3.1
Ambulatory Clinic Hammad 2011 -4.60 0.4 -5.5 -3.7 -10.5 0.00 110 89 3.0
Ambulatory Clinic Hedegaard 2015 -1.50 0.2 -1.8 -1.2 -8.6 0.00 231 285 3.1
Ambulatory Clinic Hunt 2008 -5.00 0.7 -6.4 -3.6 -7.2 0.00 142 130 3.0
Ambulatory Clinic Jacobs 2012 -10.60 0.4 -11.3 -9.9 -28.1 0.00 72 92 3.0
Ambulatory Clinic Jarab 2012 -6.90 0.1 -7.1 -6.7 -57.7 0.00 77 79 3.1
Ambulatory Clinic Korcegez 2017 -8.20 0.6 -9.5 -6.9 -12.6 0.00 75 77 3.0
Ambulatory Clinic Morgado 2011 -6.80 0.2 -7.2 -6.4 -37.4 0.00 76 99 3.1
Ambulatory Clinic Mourao 2013 -11.50 0.2 -11.9 -11.1 -53.7 0.00 50 50 3.1
Ambulatory Clinic Obreli-Neto 2011 -22.60 0.1 -22.9 -22.3 -164.9 0.00 97 97 3.1
Ambulatory Clinic Okamoto 2001 -7.90 0.3 -8.4 -7.4 -30.9 0.00 164 166 3.1
Ambulatory Clinic Plaster 2012 -10.00 0.3 -10.5 -9.5 -39.1 0.00 34 29 3.1
Ambulatory Clinic Polgreen 2015 -5.80 0.2 -6.3 -5.3 -24.4 0.00 401 224 3.1
Ambulatory Clinic Rothman 2005 -15.00 0.1 -15.3 -14.7 -110.4 0.00 112 105 3.1
Ambulatory Clinic Sanchez-guerra 2018 -7.00 0.3 -7.7 -6.3 -20.6 0.00 31 29 3.0
Ambulatory Clinic Shao 2017 -3.90 0.6 -5.1 -2.7 -6.5 0.00 100 99 3.0
Ambulatory Clinic Simpson 2011 -4.90 0.4 -5.7 -4.1 -11.6 0.00 129 131 3.0
Ambulatory Clinic Sookaneknun 2004 -5.70 0.5 -6.7 -4.7 -11.7 0.00 118 117 3.0
Ambulatory Clinic Tobari 2010 -1.50 0.1 -1.7 -1.3 -15.1 0.00 66 66 3.1
Ambulatory Clinic Wal 2013 -12.20 0.4 -13.0 -11.4 -31.8 0.00 54 48 3.0
Ambulatory Clinic -8.34 0.9 -10.1 -6.6 -9.5 0.00 3471 3345
Community Pharmacy Amariles 2012 -6.50 0.2 -6.9 -6.1 -31.9 0.00 356 358 5.5
Community Pharmacy Bajorek 2016 -13.00 1.2 -15.4 -10.6 -10.5 0.00 27 11 4.9
Community Pharmacy Basheti 2016 -12.40 0.6 -13.5 -11.3 -22.2 0.00 82 78 5.4
Community Pharmacy Fornos 2006 -9.00 0.6 -10.1 -7.9 -16.0 0.00 56 56 5.4
Community Pharmacy Garcao 2002 -18.40 1.5 -21.2 -15.6 -12.7 0.00 41 41 4.7
Community Pharmacy Jahangard-Rafsanjani 2014 -3.00 0.2 -3.5 -2.5 -12.9 0.00 45 40 5.5
Community Pharmacy Kjeldsen 2014 -5.30 0.3 -5.8 -4.8 -19.3 0.00 70 102 5.5
Community Pharmacy Krass 2007 -4.80 0.4 -5.5 -4.1 -13.7 0.00 87 92 5.5
Community Pharmacy Lugo De Ortellado 2008 -25.30 1.1 -27.4 -23.2 -23.5 0.00 33 28 5.0
Community Pharmacy Park 1996 -13.00 1.9 -16.7 -9.3 -6.9 0.00 23 26 4.2
Community Pharmacy Paulo 2016 -1.60 0.2 -2.0 -1.2 -8.7 0.00 47 42 5.5
Community Pharmacy Planas 2009 -20.10 1.3 -22.7 -17.5 -15.2 0.00 25 15 4.8
Community Pharmacy Robinson 2010 -7.10 0.1 -7.3 -6.9 -64.0 0.00 78 62 5.5
Community Pharmacy Skowron 2010 -1.00 0.3 -1.7 -0.3 -2.9 0.00 28 56 5.5
Community Pharmacy Stewart 2014 -8.70 0.5 -9.6 -7.8 -18.1 0.00 176 176 5.4
Community Pharmacy Torres 2009 -6.20 0.2 -6.6 -5.8 -28.2 0.00 183 183 5.5
Community Pharmacy Villeneuve 2010 -1.30 0.1 -1.5 -1.1 -16.1 0.00 108 117 5.5
Community Pharmacy Wang 2011 -9.00 0.8 -10.6 -7.4 -11.2 0.00 29 30 5.2
Community Pharmacy Zillich 2005 -4.40 0.2 -4.8 -4.0 -20.5 0.00 64 61 5.5
Community Pharmacy -8.64 0.8 -10.2 -7.1 -10.8 0.00 1558 1574
Overall -8.50 0.6 -9.7 -7.3 -14.4 0.00 5029 4919
-28.00 -14.00 0.00 14.00 28.00
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Figure S2. Raw mean difference on Diastolic Blood Pressure in millimetres of mercury. 
CI: confidence interval. 
  
Group by
Setting
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Standard Lower Upper Med Usual Relative Relative 
in means error limit limit Z-Value p-Value Review Care weight weight
Ambulatory Clinic Aguiar 2016 -3.10 0.12 -3.34 -2.86 -25.24 0.00 36 37 3.1
Ambulatory Clinic Al Mazroui 2009 -9.10 0.17 -9.43 -8.77 -54.81 0.00 117 117 3.1
Ambulatory Clinic Albsoul-Younes 2011 -3.30 0.33 -3.94 -2.66 -10.08 0.00 130 123 3.1
Ambulatory Clinic Azevedo 2017 -9.70 0.57 -10.81 -8.59 -17.11 0.00 33 30 3.1
Ambulatory Clinic Bogden 1998 -11.00 0.47 -11.93 -10.07 -23.22 0.00 49 46 3.1
Ambulatory Clinic Carter 2008 -3.30 0.28 -3.85 -2.75 -11.71 0.00 101 78 3.1
Ambulatory Clinic Carter 2009 -5.20 0.16 -5.52 -4.88 -32.08 0.00 192 210 3.1
Ambulatory Clinic Chan 2012 -2.10 0.10 -2.29 -1.91 -21.68 0.00 51 54 3.1
Ambulatory Clinic Clifford 2005 -3.00 0.15 -3.30 -2.70 -19.76 0.00 92 88 3.1
Ambulatory Clinic de Castro 2015 -2.00 0.28 -2.54 -1.46 -7.23 0.00 30 34 3.1
Ambulatory Clinic Ebid 2014 -6.80 0.09 -6.97 -6.63 -76.72 0.00 140 140 3.1
Ambulatory Clinic Firminho 2015 -6.70 0.42 -7.51 -5.89 -16.13 0.00 26 30 3.1
Ambulatory Clinic Green 2008 -3.60 0.68 -4.93 -2.27 -5.31 0.00 237 247 3.0
Ambulatory Clinic Hammad 2011 -7.00 0.06 -7.12 -6.88 -114.94 0.00 110 89 3.1
Ambulatory Clinic Hedegaard 2015 -0.20 0.09 -0.39 -0.01 -2.12 0.03 231 285 3.1
Ambulatory Clinic Hunt 2008 -1.00 0.39 -1.77 -0.23 -2.53 0.01 142 130 3.1
Ambulatory Clinic Jacobs 2012 -6.70 0.28 -7.26 -6.14 -23.52 0.00 72 92 3.1
Ambulatory Clinic Jarab 2012 -8.90 0.09 -9.08 -8.72 -94.93 0.00 77 79 3.1
Ambulatory Clinic Korcegez 2017 -3.40 0.46 -4.29 -2.51 -7.45 0.00 75 77 3.1
Ambulatory Clinic Morgado 2011 -1.90 0.36 -2.61 -1.19 -5.26 0.00 76 99 3.1
Ambulatory Clinic Mourao 2013 -0.50 0.12 -0.73 -0.27 -4.22 0.00 50 50 3.1
Ambulatory Clinic Obreli-Neto 2011 -12.90 0.16 -13.22 -12.58 -78.66 0.00 97 97 3.1
Ambulatory Clinic Okamoto 2001 -3.70 0.22 -4.13 -3.27 -16.71 0.00 164 166 3.1
Ambulatory Clinic Plaster 2012 -3.00 0.34 -3.67 -2.33 -8.74 0.00 34 29 3.1
Ambulatory Clinic Polgreen 2015 -2.50 0.12 -2.74 -2.26 -20.04 0.00 401 224 3.1
Ambulatory Clinic Rothman 2005 -9.00 0.13 -9.25 -8.75 -70.00 0.00 112 105 3.1
Ambulatory Clinic Sanchez-guerra 2018 -1.10 0.26 -1.60 -0.60 -4.27 0.00 31 29 3.1
Ambulatory Clinic Shao 2017 -3.40 0.39 -4.16 -2.64 -8.80 0.00 100 99 3.1
Ambulatory Clinic Simpson 2011 -2.90 0.12 -3.13 -2.67 -25.14 0.00 129 131 3.1
Ambulatory Clinic Sookaneknun 2004 -2.30 0.28 -2.86 -1.74 -8.10 0.00 118 117 3.1
Ambulatory Clinic Tobari 2010 -0.80 0.05 -0.90 -0.70 -15.36 0.00 66 66 3.1
Ambulatory Clinic Wal 2013 -5.10 0.41 -5.90 -4.30 -12.47 0.00 54 48 3.1
Ambulatory Clinic -4.53 0.62 -5.75 -3.32 -7.29 0.00 3373 3246
Community Pharmacy Amariles 2012 -2.40 0.13 -2.65 -2.15 -18.69 0.00 356 358 6.0
Community Pharmacy Bajorek 2016 -8.00 0.58 -9.14 -6.86 -13.77 0.00 10 11 5.6
Community Pharmacy Basheti 2016 -6.60 0.06 -6.72 -6.48 -111.04 0.00 82 78 6.1
Community Pharmacy Fornos 2006 -2.00 0.27 -2.53 -1.47 -7.40 0.00 56 56 6.0
Community Pharmacy Garcao 2002 -7.10 0.79 -8.65 -5.55 -8.96 0.00 41 41 5.3
Community Pharmacy Jahangard-Rafsanjani 2014 -1.80 0.11 -2.02 -1.58 -15.93 0.00 45 40 6.1
Community Pharmacy Krass 2007 -1.40 0.06 -1.51 -1.29 -24.54 0.00 87 92 6.1
Community Pharmacy Lugo De Ortellado 2008 -4.40 0.21 -4.81 -3.99 -20.80 0.00 33 28 6.0
Community Pharmacy Park 1996 -5.00 0.64 -6.25 -3.75 -7.87 0.00 23 26 5.5
Community Pharmacy Paulo 2016 -0.50 0.17 -0.84 -0.16 -2.88 0.00 47 42 6.0
Community Pharmacy Robinson 2010 -1.90 0.10 -2.09 -1.71 -19.38 0.00 78 62 6.1
Community Pharmacy Skowron 2010 -1.00 0.36 -1.70 -0.30 -2.79 0.01 28 56 5.9
Community Pharmacy Stewart 2014 -0.30 0.22 -0.73 0.13 -1.36 0.17 176 176 6.0
Community Pharmacy Torres 2009 -2.50 0.06 -2.62 -2.38 -41.28 0.00 183 183 6.1
Community Pharmacy Villeneuve 2010 -2.00 0.05 -2.11 -1.89 -37.30 0.00 108 117 6.1
Community Pharmacy Wang 2011 -4.10 0.80 -5.67 -2.53 -5.12 0.00 29 30 5.3
Community Pharmacy Zillich 2005 -3.20 0.15 -3.50 -2.90 -20.65 0.00 64 61 6.0
Community Pharmacy -3.13 0.50 -4.11 -2.14 -6.23 0.00 1446 1457
Overall -3.68 0.39 -4.45 -2.92 -9.43 0.00 4819 4703
-14.00 -7.00 0.00 7.00 14.00
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Figure S3. Raw mean difference on glycated hemoglobin (HbA1C) in percentage. 
CI: confidence interval.  
Group by
Setting
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Standard Lower Upper Med Usual Relative Relative 
in means error limit limit Z-Value p-Value Review Care weight weight
Ambulatory Clinic Abuloha 2016 -0.90 0.12 -1.13 -0.67 -7.73 0.00 45 43 5.4
Ambulatory Clinic Aguiar 2016 -0.70 0.01 -0.73 -0.67 -49.47 0.00 36 37 5.7
Ambulatory Clinic Al Mazroui 2009 -1.50 0.01 -1.52 -1.48 -134.19 0.00 117 117 5.7
Ambulatory Clinic Chan 2012 -1.20 0.14 -1.46 -0.94 -8.88 0.00 51 54 5.3
Ambulatory Clinic Chen 2016 -1.40 0.07 -1.54 -1.26 -19.47 0.00 50 50 5.6
Ambulatory Clinic Choe 2005 -1.20 0.10 -1.40 -1.00 -11.80 0.00 36 29 5.4
Ambulatory Clinic Clifford 2002 -0.20 0.03 -0.25 -0.15 -7.69 0.00 48 25 5.6
Ambulatory Clinic Clifford 2005 -0.50 0.01 -0.52 -0.48 -40.69 0.00 92 88 5.7
Ambulatory Clinic Jacobs 2012 -1.00 0.07 -1.15 -0.85 -13.46 0.00 72 92 5.5
Ambulatory Clinic Jameson 2010 -1.10 0.03 -1.17 -1.03 -32.93 0.00 52 51 5.6
Ambulatory Clinic Jarab 2012 -0.90 0.03 -0.96 -0.84 -28.85 0.00 77 79 5.6
Ambulatory Clinic Korcegez 2017 -0.70 0.04 -0.78 -0.62 -16.82 0.00 75 77 5.6
Ambulatory Clinic Mourao 2013 -1.40 0.02 -1.44 -1.36 -62.76 0.00 50 50 5.6
Ambulatory Clinic Obreli-Neto 2011 -0.70 0.03 -0.76 -0.64 -24.28 0.00 97 97 5.6
Ambulatory Clinic Rothman 2005 -0.90 0.02 -0.94 -0.86 -41.87 0.00 99 95 5.7
Ambulatory Clinic Shao 2017 -0.80 0.15 -1.10 -0.50 -5.20 0.00 100 99 5.2
Ambulatory Clinic Simpson 2011 -0.30 0.01 -0.32 -0.28 -37.07 0.00 131 129 5.7
Ambulatory Clinic Wishah 2014 -1.40 0.10 -1.59 -1.21 -14.60 0.00 52 54 5.5
Ambulatory Clinic -0.93 0.12 -1.17 -0.69 -7.63 0.00 1280 1266
Community Pharmacy Chung 2014 -1.20 0.04 -1.27 -1.13 -32.03 0.00 120 121 15.1
Community Pharmacy Doucette 2009 -0.40 0.21 -0.80 0.00 -1.94 0.05 36 42 10.8
Community Pharmacy Fornos 2006 -1.20 0.03 -1.27 -1.13 -35.90 0.00 56 56 15.2
Community Pharmacy Jahangard-Rafsanjani 2014 -0.50 0.04 -0.57 -0.43 -13.36 0.00 45 40 15.1
Community Pharmacy Krass 2007 -0.70 0.02 -0.74 -0.66 -30.99 0.00 125 107 15.3
Community Pharmacy Paulo 2016 -0.20 0.13 -0.46 0.06 -1.52 0.13 47 42 13.1
Community Pharmacy Taylor 2016 -0.50 0.01 -0.52 -0.48 -45.80 0.00 53 46 15.3
Community Pharmacy -0.69 0.12 -0.94 -0.45 -5.55 0.00 482 454
Overall -0.81 0.09 -0.99 -0.64 -9.33 0.00 1762 1720
-1.60 -0.80 0.00 0.80 1.60
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Figure S4. Raw mean difference on fasting glucose in milligrams per decilitre. 
CI: confidence interval. 
  
Group by
Setting
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Standard Lower Upper Med Usual Relative Relative 
in means error limit limit Z-Value p-Value Review Care weight weight
Ambulatory Clinic Abuloha 2016 -42.0 1.78 -45.5 -38.5 -23.58 0.00 45 43 7.7
Ambulatory Clinic Al Mazroui 2009 -40.8 2.43 -45.6 -36.0 -16.76 0.00 117 117 7.7
Ambulatory Clinic Azevedo 2017 -22.4 4.24 -30.7 -14.1 -5.29 0.00 33 30 7.4
Ambulatory Clinic Clifford 2005 -21.7 0.29 -22.3 -21.1 -73.99 0.00 92 88 7.8
Ambulatory Clinic Firminho 2015 -7.2 2.60 -12.3 -2.1 -2.77 0.01 26 30 7.7
Ambulatory Clinic Hammad 2011 -3.3 0.37 -4.0 -2.6 -8.83 0.00 110 89 7.8
Ambulatory Clinic Jarab 2012 -57.6 0.74 -59.1 -56.1 -77.41 0.00 77 79 7.8
Ambulatory Clinic Korcegez 2017 -7.7 2.01 -11.6 -3.8 -3.82 0.00 75 77 7.7
Ambulatory Clinic Mourao 2013 -34.8 0.57 -35.9 -33.7 -60.76 0.00 50 50 7.8
Ambulatory Clinic Obreli-Neto 2011 -28.3 0.36 -29.0 -27.6 -79.35 0.00 97 97 7.8
Ambulatory Clinic Plaster 2012 -60.0 0.60 -61.2 -58.8 -99.51 0.00 34 29 7.8
Ambulatory Clinic Shao 2017 -24.5 2.63 -29.7 -19.3 -9.31 0.00 100 99 7.7
Ambulatory Clinic Wishah 2014 -51.7 4.74 -61.0 -42.4 -10.91 0.00 52 54 7.3
Ambulatory Clinic -30.9 5.15 -41.0 -20.8 -6.00 0.00 908 882
Community Pharmacy Basheti 2016 -19.5 2.37 -24.2 -14.8 -8.22 0.00 82 78 25.2
Community Pharmacy Chung 2014 -43.3 1.95 -47.1 -39.5 -22.21 0.00 120 121 25.3
Community Pharmacy Paulo 2016 -7.9 5.80 -19.3 3.5 -1.36 0.17 47 42 24.0
Community Pharmacy Villeneuve 2010 -2.0 0.32 -2.6 -1.4 -6.34 0.00 108 117 25.5
Community Pharmacy -18.3 11.62 -41.1 4.5 -1.57 0.12 357 358
Overall -28.8 4.71 -38.1 -19.6 -6.12 0.00 1265 1240
-62.00 -31.00 0.00 31.00 62.00
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Figure S5. Raw mean difference on total cholesterol in milligrams per decilitre. 
CI: confidence interval. 
 
Group by
Setting
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Standard Lower Upper Med Usual Relative Relative 
in means error limit limit Z-Value p-Value Review Care weight weight
Ambulatory Clinic Al Mazroui 2009 -32.4 1.09 -34.5 -30.3 -29.82 0.00 117 117 5.9
Ambulatory Clinic Azevedo 2017 -12.0 1.92 -15.8 -8.2 -6.23 0.00 33 33 5.8
Ambulatory Clinic Bogden 1997 -31.0 0.44 -31.9 -30.1 -70.55 0.00 47 47 6.0
Ambulatory Clinic Chan 2012 -12.3 0.33 -13.0 -11.6 -36.72 0.00 51 54 6.0
Ambulatory Clinic Clifford 2005 -3.8 0.25 -4.3 -3.3 -15.06 0.00 92 88 6.0
Ambulatory Clinic Firminho 2015 -13.7 2.13 -17.9 -9.5 -6.43 0.00 21 15 5.7
Ambulatory Clinic Jarab 2012 -31.2 0.41 -32.0 -30.4 -76.94 0.00 77 79 6.0
Ambulatory Clinic Korcegez 2017 -6.8 1.24 -9.2 -4.4 -5.47 0.00 77 75 5.9
Ambulatory Clinic Lee 2009 -23.6 1.48 -26.5 -20.7 -15.95 0.00 58 60 5.9
Ambulatory Clinic Mourao 2013 -25.6 0.55 -26.7 -24.5 -46.55 0.00 50 50 5.9
Ambulatory Clinic Obreli-Neto 2011 -21.0 2.32 -25.6 -16.4 -9.04 0.00 97 97 5.7
Ambulatory Clinic Plaster 2012 -24.0 0.91 -25.8 -22.2 -26.48 0.00 34 29 5.9
Ambulatory Clinic Rothman 2005 -15.0 0.45 -15.9 -14.1 -33.63 0.00 99 95 6.0
Ambulatory Clinic Shao 2017 -19.0 0.35 -19.7 -18.3 -54.51 0.00 100 99 6.0
Ambulatory Clinic Simpson 2011 -5.4 0.21 -5.8 -5.0 -25.38 0.00 131 129 6.0
Ambulatory Clinic Villa 2009 -22.0 0.90 -23.8 -20.2 -24.47 0.00 85 57 5.9
Ambulatory Clinic Wishah 2014 -7.5 2.42 -12.2 -2.8 -3.10 0.00 52 54 5.7
Ambulatory Clinic -18.0 2.62 -23.2 -12.9 -6.88 0.00 1221 1178
Community Pharmacy Amariles 2012 -4.6 0.83 -6.2 -3.0 -5.56 0.00 356 358 14.7
Community Pharmacy Fornos 2006 -19.0 0.73 -20.4 -17.6 -26.18 0.00 56 56 14.7
Community Pharmacy Krass 2007 0.0 0.25 -0.5 0.5 0.00 1.00 112 98 14.8
Community Pharmacy Nola 2000 -5.6 2.21 -9.9 -1.3 -2.53 0.01 25 26 13.7
Community Pharmacy Paulo 2016 -10.0 0.39 -10.8 -9.2 -25.70 0.00 47 42 14.8
Community Pharmacy Paulos 2005 -22.9 3.23 -29.2 -16.6 -7.09 0.00 23 19 12.6
Community Pharmacy Villeneuve 2010 -7.7 0.81 -9.3 -6.1 -9.55 0.00 108 117 14.7
Community Pharmacy -9.7 2.92 -15.5 -4.0 -3.33 0.00 727 716
Overall -14.3 1.95 -18.2 -10.5 -7.34 0.00 1948 1894
-35.00 -17.50 0.00 17.50 35.00
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Figure S6. Raw mean difference on Low Density Lipoprotein (LDL) cholesterol in milligrams per decilitre.  
CI: confidence interval. 
  
Group by
Setting
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Standard Lower Upper Med Usual Relative Relative 
in means error limit limit Z-Value p-Value Review Care weight weight
Ambulatory Clinic Aguiar 2016 0.0 0.369 -0.7 0.7 0.00 1.00 36 37 6.8
Ambulatory Clinic Al Mazroui 2009 -29.0 1.276 -31.5 -26.5 -22.74 0.00 117 117 6.6
Ambulatory Clinic Azevedo 2017 -14.0 0.611 -15.2 -12.8 -22.92 0.00 33 33 6.8
Ambulatory Clinic Chan 2012 -12.4 0.270 -12.9 -11.9 -45.98 0.00 51 54 6.8
Ambulatory Clinic Firminho 2015 -6.0 3.221 -12.3 0.3 -1.86 0.06 21 15 5.7
Ambulatory Clinic Jarab 2012 -23.2 0.444 -24.1 -22.3 -52.21 0.00 77 79 6.8
Ambulatory Clinic Korcegez 2017 -6.6 1.335 -9.2 -4.0 -4.94 0.00 77 75 6.6
Ambulatory Clinic Lee 2009 -22.8 1.184 -25.1 -20.5 -19.25 0.00 58 60 6.7
Ambulatory Clinic Mourao 2013 -24.5 0.480 -25.4 -23.6 -51.01 0.00 50 50 6.8
Ambulatory Clinic Obreli-Neto 2011 -13.9 0.083 -14.1 -13.7 -167.86 0.00 97 97 6.9
Ambulatory Clinic Plaster 2012 -27.0 0.394 -27.8 -26.2 -68.50 0.00 34 29 6.8
Ambulatory Clinic Shao 2017 -11.2 0.413 -12.0 -10.4 -27.13 0.00 100 99 6.8
Ambulatory Clinic Simpson 2011 -5.0 0.168 -5.3 -4.7 -29.77 0.00 131 129 6.9
Ambulatory Clinic Villa 2009 -23.0 0.488 -24.0 -22.0 -47.15 0.00 85 57 6.8
Ambulatory Clinic Wishah 2014 -9.3 2.530 -14.3 -4.3 -3.68 0.00 52 54 6.1
Ambulatory Clinic -15.3 1.843 -18.9 -11.7 -8.31 0.00 1019 985
Community Pharmacy Doucette 2009 -7.6 0.335 -8.3 -6.9 -22.72 0.00 36 42 21.1
Community Pharmacy Fornos 2006 -12.0 0.506 -13.0 -11.0 -23.69 0.00 56 56 20.5
Community Pharmacy Nola 2000 -10.4 1.309 -13.0 -7.8 -7.94 0.00 25 26 15.9
Community Pharmacy Paulo 2016 -5.7 0.318 -6.3 -5.1 -17.91 0.00 47 42 21.2
Community Pharmacy Villeneuve 2010 -8.8 0.282 -9.4 -8.2 -31.25 0.00 108 117 21.3
Community Pharmacy -8.8 1.012 -10.8 -6.8 -8.70 0.00 272 283
Overall -10.3 0.887 -12.0 -8.6 -11.63 0.00 1291 1268
-32.00 -16.00 0.00 16.00 32.00
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Figure S7. Raw mean difference on High Density Lipoprotein (HDL) cholesterol in milligrams per decilitre. 
CI: confidence interval. 
  
Group by
Setting
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Standard Lower Upper Med Usual Relative Relative 
in means error limit limit Z-Value p-Value Review Care weight weight
Ambulatory Clinic Al Mazroui 2009 4.30 0.20 3.90 4.70 21.12 0.00 117 117 6.3
Ambulatory Clinic Azevedo 2017 8.50 0.17 8.18 8.82 51.50 0.00 33 30 6.3
Ambulatory Clinic Chan 2012 0.10 0.09 -0.07 0.27 1.16 0.25 51 54 6.3
Ambulatory Clinic Clifford 2005 2.00 0.09 1.82 2.18 21.24 0.00 92 88 6.3
Ambulatory Clinic Firminho 2015 3.30 0.66 2.01 4.59 5.01 0.00 21 15 6.2
Ambulatory Clinic Hammad 2011 5.00 0.13 4.74 5.26 37.21 0.00 110 89 6.3
Ambulatory Clinic Jarab 2012 5.80 0.23 5.36 6.24 25.75 0.00 77 79 6.3
Ambulatory Clinic Korcegez 2017 0.00 0.11 -0.22 0.22 0.00 1.00 77 75 6.3
Ambulatory Clinic Lee 2009 0.70 0.40 -0.08 1.48 1.76 0.08 58 60 6.2
Ambulatory Clinic Mourao 2013 4.50 0.12 4.27 4.73 38.95 0.00 50 50 6.3
Ambulatory Clinic Obreli-Neto 2011 10.00 0.05 9.90 10.10 196.49 0.00 97 97 6.3
Ambulatory Clinic Plaster 2012 11.30 0.04 11.23 11.37 314.82 0.00 34 29 6.3
Ambulatory Clinic Shao 2017 4.20 0.32 3.58 4.82 13.28 0.00 100 99 6.2
Ambulatory Clinic Simpson 2011 0.20 0.28 -0.34 0.74 0.73 0.47 131 129 6.3
Ambulatory Clinic Villa 2009 3.00 0.51 2.00 4.00 5.85 0.00 85 57 6.2
Ambulatory Clinic Wishah 2014 2.20 0.18 1.86 2.54 12.51 0.00 52 54 6.3
Ambulatory Clinic 4.07 1.23 1.66 6.49 3.31 0.00 1185 1122
Community Pharmacy Fornos 2006 0.20 0.12 -0.03 0.43 1.67 0.09 56 56 30.1
Community Pharmacy Nola 2000 3.80 0.80 2.23 5.37 4.73 0.00 25 26 7.8
Community Pharmacy Paulo 2016 0.40 0.11 0.19 0.61 3.79 0.00 47 42 30.6
Community Pharmacy Villeneuve 2010 0.90 0.07 0.76 1.04 12.91 0.00 108 117 31.5
Community Pharmacy 0.76 0.26 0.26 1.27 2.95 0.00 236 241
Overall 0.90 0.25 0.41 1.40 3.57 0.00 1421 1363
-12.00 -6.00 0.00 6.00 12.00
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Figure S8. Raw mean difference on Triglycerides in milligrams per decilitre. 
CI: confidence interval. 
Group by
Setting
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Standard Lower Upper Med Usual Relative Relative 
in means error limit limit Z-Value p-Value Review Care weight weight
Ambulatory Clinic Al Mazroui 2009 -47.8 2.72 -53.1 -42.5 -17.58 0.00 117 117 6.4
Ambulatory Clinic Azevedo 2017 -63.9 9.16 -81.9 -45.9 -6.97 0.00 33 30 5.2
Ambulatory Clinic Chan 2012 0.0 6.25 -12.2 12.2 0.00 1.00 51 54 5.9
Ambulatory Clinic Clifford 2005 -51.1 5.14 -61.2 -41.0 -9.93 0.00 92 88 6.1
Ambulatory Clinic Firminho 2015 -52.4 3.16 -58.6 -46.2 -16.60 0.00 21 15 6.4
Ambulatory Clinic Hammad 2011 -16.9 0.59 -18.1 -15.7 -28.60 0.00 110 89 6.6
Ambulatory Clinic Jarab 2012 -62.1 1.58 -65.2 -59.0 -39.26 0.00 77 79 6.5
Ambulatory Clinic Korcegez 2017 -1.2 0.64 -2.4 0.0 -1.88 0.06 77 75 6.6
Ambulatory Clinic Lee 2009 -15.0 1.45 -17.8 -12.2 -10.33 0.00 58 60 6.5
Ambulatory Clinic Mourao 2013 -34.0 0.84 -35.6 -32.4 -40.49 0.00 50 50 6.6
Ambulatory Clinic Obreli-Neto 2011 -51.6 0.87 -53.3 -49.9 -59.48 0.00 97 97 6.6
Ambulatory Clinic Plaster 2012 -12.0 1.11 -14.2 -9.8 -10.85 0.00 34 29 6.5
Ambulatory Clinic Shao 2017 -25.7 5.37 -36.2 -15.2 -4.78 0.00 100 99 6.0
Ambulatory Clinic Simpson 2011 -16.0 0.50 -17.0 -15.0 -31.85 0.00 131 129 6.6
Ambulatory Clinic Villa 2009 -77.0 4.89 -86.6 -67.4 -15.74 0.00 85 57 6.1
Ambulatory Clinic Wishah 2014 -37.0 7.73 -52.1 -21.9 -4.79 0.00 52 54 5.5
Ambulatory Clinic -34.8 4.59 -43.8 -25.8 -7.59 0.00 1185 1122
Community Pharmacy Basheti 2016 -31.9 6.74 -45.1 -18.7 -4.73 0.00 82 78 13.2
Community Pharmacy Fornos 2006 -32.0 7.04 -45.8 -18.2 -4.55 0.00 56 56 13.0
Community Pharmacy Krass 2007 -17.7 0.52 -18.7 -16.7 -33.97 0.00 112 97 17.1
Community Pharmacy Nola 2000 -2.8 8.15 -18.8 13.2 -0.34 0.73 25 26 12.0
Community Pharmacy Paulo 2016 -18.5 1.19 -20.8 -16.2 -15.56 0.00 47 42 17.0
Community Pharmacy Paulos 2005 -80.0 9.69 -99.0 -61.0 -8.26 0.00 23 19 10.6
Community Pharmacy Villeneuve 2010 0.0 0.45 -0.9 0.9 0.00 1.00 108 117 17.1
Community Pharmacy -23.4 5.12 -33.4 -13.3 -4.57 0.00 453 435
Overall -29.7 3.42 -36.4 -23.0 -8.70 0.00 1638 1557
-100.00 -50.00 0.00 50.00 100.00
Favours Med Review Favours Usual Care
Mean difference in Triglycerides
Meta Analysis
3 
23 
14 
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